FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / PLoS One / Regenerative therapies for equine degenerative joint disease...
PloS one2014; 9(1); e85917; doi: 10.1371/journal.pone.0085917

Regenerative therapies for equine degenerative joint disease: a preliminary study.

Abstract: Degenerative joint disease (DJD) is a major cause of reduced athletic function and retirement in equine performers. For this reason, regenerative therapies for DJD have gained increasing interest. Platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) were isolated from a 6-year-old donor horse. MSCs were either used in their native state or after chondrogenic induction. In an initial study, 20 horses with naturally occurring DJD in the fetlock joint were divided in 4 groups and injected with the following: 1) PRP; 2) MSCs; 3) MSCs and PRP; or 4) chondrogenic induced MSCs and PRP. The horses were then evaluated by means of a clinical scoring system after 6 weeks (T1), 12 weeks (T2), 6 months (T3) and 12 months (T4) post injection. In a second study, 30 horses with the same medical background were randomly assigned to one of the two combination therapies and evaluated at T1. The protein expression profile of native MSCs was found to be negative for major histocompatibility (MHC) II and p63, low in MHC I and positive for Ki67, collagen type II (Col II) and Vimentin. Chondrogenic induction resulted in increased mRNA expression of aggrecan, Col II and cartilage oligomeric matrix protein (COMP) as well as in increased protein expression of p63 and glycosaminoglycan, but in decreased protein expression of Ki67. The combined use of PRP and MSCs significantly improved the functionality and sustainability of damaged joints from 6 weeks until 12 months after treatment, compared to PRP treatment alone. The highest short-term clinical evolution scores were obtained with chondrogenic induced MSCs and PRP. This study reports successful in vitro chondrogenic induction of equine MSCs. In vivo application of (induced) MSCs together with PRP in horses suffering from DJD in the fetlock joint resulted in a significant clinical improvement until 12 months after treatment.
Get Full Text
Publication Date: 2014-01-20 PubMed ID: 24465787PubMed Central: PMC3896436DOI: 10.1371/journal.pone.0085917Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article is about a preliminary study conducted to evaluate the effectiveness of regenerative therapies, including platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs), in treating degenerative joint disease (DJD) in horses. The results showed significant clinical improvement in the treated horses, especially when both PRP and induced MSCs were used.

About Degenerative Joint Disease and Regenerative Therapies

  • DJD is a common disease in horses that often leads to decreased athletic performance and premature retirement. It involves deterioration of the joints, causing pain and functional impairment.
  • Regenerative therapies have emerged as a potential treatment for DJD. Among these therapies, PRP and MSCs have garnered significant interest.
  • PRP is a blood plasma that has been enriched with platelets. When injected into damaged tissues, PRP can potentially speed up healing.
  • MSCs are a type of stem cell capable of differentiating into a variety of cell types, including those that make up the cartilage in joints. Developers of the therapy hope that injecting MSCs into a damaged joint will encourage the development of new, healthy cartilage.

Details of the Study

  • The research involved two studies. The first included 20 horses with naturally occurring DJD. They were divided into four groups and received injections of PRP, MSCs, a combination of both, or a combination of PRP and MSCs that had been induced to become cartilage-producing cells.
  • The horses were then monitored over a period of 12 months. Assessments were made at 6 weeks, 12 weeks, 6 months, and 12 months following the injection. The researchers used a clinical scoring system to evaluate the condition of the horses.
  • In the second study, 30 additional horses with DJD were randomly assigned to one of the two combination therapies and evaluated 6 weeks (T1) after treatment.

Study Findings

  • The researchers found that the protein expression profile of native MSCs was negative for major histocompatibility (MHC) II and p63, low in MHC I, and positive for Ki67, Collagen type II, and Vimentin.
  • Chondrogenic induction of MSCs resulted in increased mRNA expression of aggrecan, Collagen II, and cartilage oligomeric matrix protein (COMP) along with an increase in protein expression of p63 and glycosaminoglycan (a component of cartilage) but a decrease in the protein expression of Ki67.
  • The combined use of PRP and MSCs significantly improved the functionality and sustainability of damaged joints from 6 weeks up to 12 months following treatment, compared to using PRP alone.
  • The best short-term clinical evolution scores were obtained with chondrogenic induced MSCs combined with PRP.

Conclusion

  • The study reports successful in vitro chondrogenic induction of equine MSCs. When applied in vivo (in the horse), these induced MSCs, along with PRP, resulted in significant clinical improvement in horses suffering from DJD.
  • This preliminary study provides a basis for future research and potential approval of MSC and PRP combination therapy for equine DJD.

Cite This Article

APA
Broeckx S, Zimmerman M, Crocetti S, Suls M, Mariën T, Ferguson SJ, Chiers K, Duchateau L, Franco-Obregón A, Wuertz K, Spaas JH. (2014). Regenerative therapies for equine degenerative joint disease: a preliminary study. PLoS One, 9(1), e85917. https://doi.org/10.1371/journal.pone.0085917

Publication

PloS one
ISSN: 1932-6203
NlmUniqueID: 101285081
Country: United States
Language: English
Volume: 9
Issue: 1
Pages: e85917

Researcher Affiliations

Broeckx, Sarah
  • Global Stem cell Technology, Meldert-Lummen, Belgium.
Zimmerman, Marieke
  • Equine Veterinary Practice Dr Suls, Weert, The Netherlands.
Crocetti, Sara
  • Department for Biomechanics, ETH Zurich, Zurich, Switzerland.
Suls, Marc
  • Equine Veterinary Practice Dr Suls, Weert, The Netherlands.
Mariën, Tom
  • Equitom Equine Hospital, Meldert-Lummen, Belgium.
Ferguson, Stephen J
  • Department for Biomechanics, ETH Zurich, Zurich, Switzerland ; Competence Center for Applied Biotechnology and Molecular Medicine CABMM, University of Zurich, Zurich, Switzerland.
Chiers, Koen
  • Department of Pathology, Bacteriology and Poultry Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Duchateau, Luc
  • Department of Comparative Physiology and Biometrics, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Franco-Obregón, Alfredo
  • Department for Biomechanics, ETH Zurich, Zurich, Switzerland ; Competence Center for Applied Biotechnology and Molecular Medicine CABMM, University of Zurich, Zurich, Switzerland ; Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Wuertz, Karin
  • Department for Biomechanics, ETH Zurich, Zurich, Switzerland ; Competence Center for Applied Biotechnology and Molecular Medicine CABMM, University of Zurich, Zurich, Switzerland.
Spaas, Jan H
  • Global Stem cell Technology, Meldert-Lummen, Belgium.

MeSH Terms

  • Aggrecans / metabolism
  • Animals
  • Cell Differentiation
  • Chondrogenesis / physiology
  • Collagen Type II / metabolism
  • Horses
  • Joint Diseases / metabolism
  • Joint Diseases / therapy
  • Joint Diseases / veterinary
  • Male
  • Mesenchymal Stem Cell Transplantation / methods
  • Mesenchymal Stem Cell Transplantation / veterinary
  • Platelet-Rich Plasma / metabolism
  • Treatment Outcome

Conflict of Interest Statement

Competing Interests: The authors MS, TM and JHS declare competing financial interests as shareholders in Global Stem cell Technology (GST). SB and JHS are both employed by GST and inventors of several pending patents owned by GST (PCT/EP2013/070247, PCT/EP2013/070257 and PCT/EP2013/075782). The content of this manuscript contains products under development owned by GST. This does not alter the authors’ adherence to all PLOS ONE policies on sharing data and materials.

References

This article includes 47 references
  1. Jeffcott LB, Rossdale PD, Freestone J, Frank CJ, Towers-Clark PF. An assessment of wastage in thoroughbred racing from conception to 4 years of age.. Equine Vet J 14: 185–198.
    pubmed: 7106081
  2. McIlwraith CW. Current concepts in equine degenerative joint disease.. J Am Vet Med Assoc 180: 239–250.
    pubmed: 7035425
  3. Frisbie DD. Future directions in treatment of joint disease in horses.. Vet Clin North Am Equine Pract 21: 713–724, viii.
    pubmed: 16297729
  4. Malone ED. Managing chronic arthritis.. Vet Clin North Am Equine Pract 18: 411–437.
    pubmed: 12516926
  5. Nizolek DJ, White KK. Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease. A review.. The Cornell veterinarian 71: 355–375.
    pubmed: 7032840
  6. Goodrich LR, Nixon AJ. Medical treatment of osteoarthritis in the horse - a review.. Vet J 171: 51–69.
    pubmed: 16427582
  7. Zubrod CJ, Schneider RK. Arthrodesis techniques in horses.. Vet Clin North Am Equine Pract 21: 691–711, vii.
    pubmed: 16297728
  8. Koch TG, Betts DH. Stem cell therapy for joint problems using the horse as a clinically relevant animal model.. Expert Opin Biol Ther 7: 1621–1626.
    pubmed: 17961087
  9. Berg L, Koch T, Heerkens T, Bessonov K, Thomsen P. Chondrogenic potential of mesenchymal stromal cells derived from equine bone marrow and umbilical cord blood.. Vet Comp Orthop Traumatol 22: 363–370.
    pubmed: 19750290
  10. Spaas JH, Schauwer CD, Cornillie P, Meyer E, Soom AV. Culture and characterisation of equine peripheral blood mesenchymal stromal cells.. Vet J 195: 107–113.
    pubmed: 22717781
  11. Smith RK, Webbon PM. Harnessing the stem cell for the treatment of tendon injuries: heralding a new dawn?. Brit J Sport Med 39: 582–584.
    pmc: PMC1725307pubmed: 16118291
  12. Spaas JH, Guest DJ, Van de Walle GR. Tendon regeneration in human and equine athletes: Ubi Sumus-Quo Vadimus (where are we and where are we going to)?. Sports Med 42: 871–890.
    pubmed: 22963225
  13. Frisbie DD, Cross MW, McIlwraith CW. A comparative study of articular cartilage thickness in the stifle of animal species used in human pre-clinical studies compared to articular cartilage thickness in the human knee.. Vet Comp Orthop Traumatol 19: 142–146.
    pubmed: 16971996
  14. Spaas JH, Oosterlinck M, Broeckx S, Dumoulin M, Saunders J. Treatment of equine degenerative joint disease with autologous peripheral blood-derived mesenchymal stem cells: a case report.. Vlaams Dierg Tijdschrift 81: 11–15.
  15. Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis.. J Orthop Res 27: 1675–1680.
    pubmed: 19544397
  16. McIlwraith CW, Frisbie DD, Rodkey WG, Kisiday JD, Werpy NM. Evaluation of intra-articular mesenchymal stem cells to augment healing of microfractured chondral defects.. Arthroscopy 27: 1552–1561.
    pubmed: 21862278
  17. Wilke MM, Nydam DV, Nixon AJ. Enhanced early chondrogenesis in articular defects following arthroscopic mesenchymal stem cell implantation in an equine model.. J Orthop Res 25: 913–925.
    pubmed: 17405160
  18. Beerts C, Seifert C, Zimmerman M, Felix E, Suls M. Desmitis of the accessory ligament of the equine deep digital flexor tendon: a regenerative approach.. J Tissue Sci Eng 4(1): 1–7.
  19. Broeckx S, Zimmerman M, Aerts D, Seys B, Suls M. Tenogenesis of equine peripheral blood-derived mesenchymal stem cells: in vitro versus in vivo.. J Tissue Sci Eng S11–001: 1–6.
  20. Broeckx S, Forier R, Mariën T, Suls M, Savkovic V. The influence of allogenic mesenchymal stem cells on the hematological status of horses.. J Stem Cell Res Ther 3(2): 1–6.
  21. Carrade DD, Affolter VK, Outerbridge CA, Watson JL, Galuppo LD. Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions.. Cytotherapy 13: 1180–1192.
    pubmed: 21899391
  22. Carrade DD, Owens SD, Galuppo LD, Vidal MA, Ferraro GL. Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses.. Cytotherapy 13: 419–430.
    pubmed: 21105841
  23. Fang BJ, Song YP, Lin QD, Zhang YL, Cao Y. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children.. Pediatr Transplant 11: 814–817.
    pubmed: 17910665
  24. Guest DJ, Smith MR, Allen WR. Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study.. Equine Vet J 40: 178–181.
    pubmed: 18267891
  25. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.. Transplantation 81: 1390–1397.
    pubmed: 16732175
  26. Weber CF. Modern coagulation management reduces the transfusion rate of allogenic blood products.. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie: AINS 47: 418–424; quiz 425.
    pubmed: 22744856
  27. Chong PP, Selvaratnam L, Abbas AA, Kamarul T. Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cells.. J Orthop Res: official publication of the Orthopaedic Research Society 30: 634–642.
    pubmed: 21922534
  28. Jonitz A, Lochner K, Tischer T, Hansmann D, Bader R. TGF-beta1 and IGF-1 influence the re-differentiation capacity of human chondrocytes in 3D pellet cultures in relation to different oxygen concentrations.. Int J Mol Med 30: 666–672.
    pubmed: 22736084
  29. Broeckx S, de Vries C, Suls M, Guest DJ, Spaas JH. Guidelines to optimize survival and migration capacities of equine mesenchymal stem cells.. J Stem Cell Res Ther 3: 1–5.
  30. Huang XP, Sun Z, Miyagi Y, McDonald Kinkaid H, Zhang L. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair.. Circulation 122: 2419–2429.
    pubmed: 21098445
  31. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.. Cytotherapy 8: 315–317.
    pubmed: 16923606
  32. Martinello T, Bronzini I, Maccatrozzo L, Iacopetti I, Sampaolesi M. Cryopreservation does not affect the stem characteristics of multipotent cells isolated from equine peripheral blood.. Tissue Eng Part C Methods 16: 771–781.
    pubmed: 19839741
  33. Bronzini I, Patruno M, Iacopetti I, Martinello T. Influence of temperature, time and different media on mesenchymal stromal cells shipped for clinical application.. Vet J 194: 121–123.
    pubmed: 22503718
  34. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model.. Transplantation 81: 1589–1595.
    pubmed: 16770249
  35. Lim MN, Hussin NH, Othman A, Umapathy T, Baharuddin P. Ex vivo expanded SSEA-4+ human limbal stromal cells are multipotent and do not express other embryonic stem cell markers.. Mol Vis 18: 1289–1300.
    pmc: PMC3365132pubmed: 22665977
  36. Reinshagen H, Auw-Haedrich C, Sorg RV, Boehringer D, Eberwein P. Corneal surface reconstruction using adult mesenchymal stem cells in experimental limbal stem cell deficiency in rabbits.. Acta Ophthalmol 89: 741–748.
    pubmed: 20039850
  37. Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia.. Annu Rev Pathol 5: 349–371.
    pubmed: 20078223
  38. Perry KJ, Thomas AG, Henry JJ. Expression of pluripotency factors in larval epithelia of the frog Xenopus: evidence for the presence of cornea epithelial stem cells.. Dev Biol 374: 281–294.
    pmc: PMC3558918pubmed: 23274420
  39. Lu Y, Abbassi S, Li F, Ding M, Wu G. Distinct function of P63 isoforms during embryonic skeletal development.. Gene 519: 251–259.
    pmc: PMC3628837pubmed: 23481305
  40. Mishra A, Tummala P, King A, Lee B, Kraus M. Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation.. Tissue Eng Part C Methods 15: 431–435.
    pmc: PMC2819709pubmed: 19216642
  41. Martinello T, Bronzini I, Perazzi A, Testoni S, De Benedictis GM. Effects of in vivo applications of peripheral blood-derived mesenchymal stromal cells (PB-MSCs) and platlet-rich plasma (PRP) on experimentally injured deep digital flexor tendons of sheep.. J Orthop Res 31: 306–314.
    pubmed: 22893604
  42. Chen L, Dong SW, Liu JP, Tao X, Tang KL. Synergy of tendon stem cells and platelet-rich plasma in tendon healing.. J Orthop Res 30: 991–997.
    pubmed: 22161871
  43. Maffulli N, Del Buono A. Platelet plasma rich products in musculoskeletal medicine: any evidence?. The surgeon: journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 10: 148–150.
    pubmed: 22525416
  44. Russell RP, Apostolakos J, Hirose T, Cote MP, Mazzocca AD. Variability of Platelet-rich Plasma Preparations.. Sports Med Arthrosc 21: 186–190.
    pubmed: 24212365
  45. Guest DJ, Smith MR, Allen WR. Monitoring the fate of autologous and allogeneic mesenchymal progenitor cells injected into the superficial digital flexor tendon of horses: preliminary study.. Equine Vet J 40: 178–181.
    pubmed: 18267891
  46. Jing H, Vassiliou E, Ganea D. Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells.. J Leukoc Biol 74: 868–879.
    pubmed: 12960284
  47. Mokbel AN, El Tookhy OS, Shamaa AA, Rashed LA, Sabry D. Homing and reparative effect of intra-articular injection of autologus mesenchymal stem cells in osteoarthritic animal model.. BMC Musculoskelet Disord 12: 259.
    pmc: PMC3232438pubmed: 22085445
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.